Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 685-688, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-826925
ABSTRACT
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in the treatment of various tumor types. Despite the favorable results in terms of oncological outcomes, these treatments have been associated with a variety of immune-related adverse events (irAEs). Myasthenia gravis (MG) is one of rare but life-threatening irAEs, with acute onset and rapid progression after ICI initiation. Early diagnosis and active treatment are crucial. Herein, we review recent literatures to provide guidance to frequently asked questions concerning the diagnosis and management of ICI-MG.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Diagnostic study
/
Practice guideline
/
Screening study
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS